Pharmacokinetic and Pharmacodynamic Comparison of Once‐Daily Efavirenz (400 mg vs. 600 mg) in Treatment‐Naïve HIV‐Infected Patients: Results of the ENCORE1 Study-Reference-Cited by-同舟云学术

Pharmacokinetic and Pharmacodynamic Comparison of Once‐Daily Efavirenz (400 mg vs. 600 mg) in Treatment‐Naïve HIV‐Infected Patients: Results of the ENCORE1 Study

Published:2015-07-14 Issue:4 Volume:98 Page:406-416
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Dickinson L¹,Amin J²,Else L¹,Boffito M³,Egan D¹,Owen A¹,Khoo S¹,Back D¹,Orrell C⁴,Clarke A⁵,Losso M⁶,Phanuphak P⁵,Carey D²,Cooper DA²,Emery S²,

Affiliation:

1. Department of Molecular & Clinical PharmacologyUniversity of LiverpoolLiverpool UK

2. Kirby InstituteUNSW AustraliaSydney Australia

3. Chelsea & Westminster Foundation TrustLondon UK

4. Desmond Tutu HIV FoundationCape Town South Africa

5. HIV‐NAT Thai Red Cross AIDS Research CenterBangkok Thailand

6. Hospital Ramos MejíaBuenos Aires Argentina

Funder

ENCORE1 substudies were funded through a project grant from the Australian Government National Health and Medical Research Council (NHMRC)

The Kirby Institute is funded in part by the Australian Government Department of Health and Ageing

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.156

Reference42 articles.

1. World Health Organisation.Global update on HIV treatment 2013: results impact and opportunities. (2013). Accessed 10 September 2014.

2. World Health Organisation.Key facts on global HIV epidemic and progress in 2010. (2011). Accessed 9 September 2014.

3. World Health Organisation.Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. (2013). Accessed 9 September 2014.

4. Haas D.W.et al.A phase II double‐blind placebo‐controlled dose ranging study to assess the antiretroviral activity and safety of efavirenz in combination with open‐label zidovudine with lamivudine at 36 weeks [DMP 266‐005]. The XII International AIDS Conference Geneva Switzerland. Abstract 22334 (1998).

5. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PBPK Modeling of Lamotrigine and Efavirenz during Pregnancy: Implications for Personalized Dosing and Drug-Drug Interaction Management;Pharmaceutics;2024-09-03

2. A Physiologically-Based Pharmacokinetic Simulation to Evaluate Approaches to Mitigate Efavirenz-Induced Decrease in Levonorgestrel Exposure with a Contraceptive Implant;Pharmaceutics;2024-08-07

3. Modelling the impact of initiation delay, duration and prior PrEP usage on the prophylactic efficacy of FTC/TDF-containing post-exposure prophylaxis;2024-07-22

4. Total and Free Blood and Plasma Concentration Changes in Pregnancy for Medicines Highly Bound to Plasma Proteins: Application of Physiologically Based Pharmacokinetic Modelling to Understand the Impact on Efficacy;Pharmaceutics;2023-10-13

5. Efavirenz: History, Development and Future;Biomolecules;2022-12-31